IMG_3650xlinac-AP-TB.jpg
IMG_0170x 3rts linac.jpg
amy-planning-on-eclipse-hn.jpg
IMG_3641x-console-linac-EM-MS.jpg
IMG_3161x mask painting Emily.jpg
ct-scan-team-ES-LL-EW.jpg
3DPRINT-GLred.jpg
SAR-3668xresearch-team.jpg
H-MRI.jpg

Princess Alexandra Hospital
Radiation Oncology
2024 Research Report

I am delighted to share with you the 2024 Research Report (PDF download link) for the Department of Radiation Oncology, Princess Alexandra Hospital.

During the past year we have offered 18 trials, with an additional 25 studies closed to accrual but continuing in follow-up phases. It is important to acknowledge the 894 people who have graciously agreed to participate on these studies, and the hard work of our staff from the Cancer Trials Unit who have made this possible.

This year, investigators from our department were awarded over $7.5 M in research grant funding including NHMRC and MRFF. This is a significant investment and highlights the capability, impact and promise that our work brings across Australia and beyond.  I would also like to acknowledge and thank generous funding support from Metro South Health Research Support Scheme and PA Research Foundation. Through these local competitive grant opportunities, we can encourage early-career and new research capacity within our craft groups.

In 2024 we recorded 66 peer-reviewed publications across a vast range of topics; radiotherapy technical innovation, head & neck cancer, supportive care research and brain cancers the most common themes.

This included 5 publications in Lancet Oncology and 1 in Lancet. Two of the highest impact studies were both co-authored by A/Prof David Pryor. FASTRACK II was a multicentre, non-randomised phase 2 trial of stereotactic ablative radiotherapy for primary kidney cancer and SARC032 was a randomised trial to assess the benefit of adding immunotherapy to surgery and radiation therapy in extremity soft tissue sarcoma. Both studies have defined a new standard of care in these diseases.

There were 29 conference abstracts and 56 speakers from our department involved across a range of forums representing Medical, Radiation Therapy, Medical Physics and Cancer Collaborative groups. There were also international presentations delivered in Washington, New York, San Diego and Houston in the USA, UK, Vienna and New Zealand.

You will see a number of people continue with higher degrees. I would like to congratulate A/Prof Lachlan McDowell who recently completed his PhD through University of Melbourne and received the Deans Award for Excellence in Graduate Research. In 2024, Lachlan also received the Emerging Research Award from TROG.

Dr Mihir Shanker also received the Young Professional Award at International SRS Congress 2024; Prof Prabhakar Ramachandra received the Kenneth Clarke Award from the Australian College of Physical Scientists and Engineers in Medicine; and Chelsea Cameron (QUT radiation therapy student) supervised by Dr Elizabeth Brown for Best Student paper at ASMIRT (Darwin 2024).

It is invigorating to reflect upon these significant contributions and achievements. I am grateful to Rochelle Palleson, Sharon Watson, Anna Koch, Nakia Beaton, Dr Elizabeth Brown, Dr Cathy Hargrave and Andrew Puffett who have helped to carefully curate this information and present it so professionally. All within Radiation Oncology should be proud of what we have been able to deliver over the past 12 months.

A/Prof Mark Pinkham

2024 has been a year of highlights and accolades in Radiation Oncology Trials, especially for the Genitourinary & Sarcoma Teams. The TROG 15.03 FASTRACK II Trial – Stereotactic Ablative Body Radiotherapy (SABR), investigated an alternative treatment for those patients with Renal Cell Carcinoma (RCC), who are unsuitable for surgery. The PAH team played a major role in recruiting 14 patients for this trial. This resulted in 100% local control with median 43mth follow-up. As a result, these findings were published in The Lancet Oncology and will be included into International guidelines and establish SABR as a valid treatment option for primary RCC.

The Prostate Trial PROMETHEUS, had its long term outcomes published in the European Urology Oncology journal. Again PAH teams (ROPAIR/ROPART) played a major role recruiting 33 patients to this study. The results showed a 95% 5 year control with SBRT boost for unfavourable risk prostate cancer. This outcome establishes a regimen as an alternative treatment option to brachytherapy boosts.

SARC032 Trial offered neoadjuvant RT +/-Pembrolizumab for a rare high grade sarcoma group. It was challenging to recruit patients and to coordinate this trial,  particularly across  the translational components. The combination of immunotherapy with pre-op RT has made the first significant gains for these soft tissue sarcomas in many years. PAH contributed 6 patients to this international study which found significant DFS advantage with the use of Pembrolizumab . These results were published in the Lancet as a promising new treatment option for these patients.

As previously mentioned, cancer trials continue to become more complicated, and frequently involve many modalities, such Radiation, Chemo/Immunotherapy & Surgery as demonstrated in the above trials. Without the co-operation of many hospital departments, the commitment of staff & the patients themselves who participate, it would be difficult to obtain the evidence needed to advance medical knowledge and practices to achieve improved patient outcomes and survival rates.

Currently, the Trials Teams work across the two campuses of ROPAIR & ROPART and consists of four full time & two part time Trial Coordinators. The Teams are well supported by the Medical, Nursing, Radiation Therapy, (including Clinical Trials RTQA), Administration, and other Health Professionals.

On behalf of the Cancer Trials Team, I would like to thank everyone’s participation and commitment as we continue to work on our current and upcoming trials, which assist in producing groundbreaking outcomes for our cancer patients.

Angela Byron
Clinical Nurse Consultant – Team Leader
Clinical Trial Coordinator – Radiation Oncology
Cancer Trials Unit
Princess Alexandra Hospital

Supported Studies

Recipients & Projects

1.     $ 119,808 Mark Hughes Foundation Centre for Brain Cancer Research Innovation Grant 2023
Communication and emotional support skills training for health professionals working with people with brain cancer and their families: A codesign and pilot study.
Ownsworth T, Pinkham M, 2024-2025

2.     $125,000 Metro South Health 2025 Research Support Scheme
Identifying metabolic signatures predictive of radiation therapy intra-treatment response in human papillomavirus associated oropharyngeal cancer.
Liu H, McDowell L, Gould C, Devlin A

 

3.     $125,000 Metro South Health 2024 Research Support Scheme
CanCommunicate: Optimising Communication for People with Brain Cancer and their Families.
Finch A, Pinkham M, 2023-2024

 

4.     $670,00 NHMRC Development Grant 2024.
A New Device for Targeted Radiation Therapy to Improve Cancer Patient Outcomes.
Keall P, Pryor D, 2023-2026

 

5.     $5,991,219.44 MRFF Australian Brain Cancer Research Infrastructure Grant
Supporting Australian Brain Cancer Research with an Integrated Network of Platforms.
Jeffree A, Pinkham M, 2023-2028

 

6.     $30,216 funding through Siemens Healthineers
Assessing the accuracy of Synthetic CT datasets generated from standardized MR Sim exams performed on head and neck cancer patients from radiation therapy planning.
Gould C, Devlin A, Barry T, Liu H, McDowell L, Ramachandran P

 

7.     $25,000 Metro South Health 2025 Research Support Scheme Grant
Assessment of multiparametric MRI functional imaging during radiation therapy to predict intra-treatment response in patients with head and neck cancer.
Liefman D, Liu H, Liu E, Jones E

 

8.     $125,000 Metro South Health 2025 Research Support Scheme Project Grant
Immune checkpoint inhibitor in perineural spread from cutaneous squamous cell carcinoma.
Ladwa R, Panizza B, Cooper C, Liu H, Kulasinghe A

 

9.     $287,000 NBCF-Investigator Initiated Research Scheme 2023,
Evaluation of radioresistance in personalized breast cancer models.
Bray L, Ravichandran A, Fielding A, Sim L, Ratnayake G, Jaeschke A

 

10.  $5000 Curtin University 2024 Grant Development Funding for Category 1 Research applications
Improving psychosocial support and education for Indigenous people during radiation therapy.
Halkett G, Garvey G, Brown A, Hargrave C, Burbery J.

 

11.  $10,000 Australian Society of Medical Imaging and Radiation Therapy Research Grant
Supportive care of Aboriginal and Torres Strait Islander People in receiving radiation therapy in Australia: Does healthcare professional education require improvement?
Halkett G, Brown A, Hargrave C, Burbery J, Garvey G, Sundaresan P, Dhillon H.

 

12.  $50,000 2024 Leading Innovations through New Collaborations (LINC) Grant.
A New Frontier in Treating Aggressive Cutaneous Squamous Cell Carcinomas.
Ratnayake G, Debottam S, Liu H, Thompson E.

Awards

Research and Recognition

  1. McDowell L, TROG Emerging Researcher Award – awarded TROG ASM 2024.

  2. Shanker M, International Stereotactic Radiosurgery Society Young Professional Award – awarded ISRS Congress 2024.

  3. McDowell L, 2024 Deans Award for Excellence in Graduate Research - The University of Melbourne, Faculty of Medicine, Dentistry & Health Sciences.

  4. Ramchandran P, 2024 Kenneth Clarke Journal Award – ACPSEM (Physical and Engineering Sciences in Medicine Journal) .

  5. Cameron C, 2024 Best RT Student Paper Prize - awarded ASMIRT (Darwin conference) 2024.

Presentations

International & National (Conferences, Workshops, Virtual Recordings)

  1. McDowell L. Contemporary Management of Head and Neck Cancers. ASTRO Refresher 2024. Oral presentation

  2. Gould C. MRI RT Simulation in Head and Neck: A Clinical Review.  AUS MR in RT, 2024. Oral presentation

  3. Cahill K, Hargrave C, O’Connor P, Denham M, Hearn N, Vignarajah D, Shan Z, Min M. Classification Development of the Parotid Gland Using Histogram Analysis of the Apparent Diffusion Coefficient for Parotid-Sparing Radiation Therapy Planning. AUS MR in RT, 2024. Oral presentation

  4. Miller K, Cahill K, Leppien A, Chapple C, O’Connor P, Vignarajah D, Hargrave C, Min M. Functional MRI Guided Parotid Gland Sparing Radiation Therapy: A Retrospective Planning Study. AUS MR in RT, 2024. Oral presentation

  5. Chapple C, Leppien A, Hearn N, Cahill K, Miller K, O’Connor P, Hargrave C, Vignarajah D, Min M.  Implementing a biological target volume feasibility study. AUS MR in RT, 2024. Oral presentation

  6. Brown E, Noble C. On the right track – implanted marker monitoring with ExacTrac Dynamic.  Brainlab Asia Pacific Users Meeting, Hobart, 2024. Invited speaker

  7. E. Johns, Bernard A, Nissen L, Barry T, Pinkham M, Hargrave C. Validating predictive models for normal brain dose in stereotactic radiotherapy for single brain metastases. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation

  8. Cameron C, Brown E, Pollard N. Evaluation of image verification shifts in VMAT breast and nodal patients and potential influencing factors. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation.  Awarded Best RT Student Paper Prize

  9. McCullough B, Burbery J, Chamunyonga C, Naidoo T. Development of a cultural capability tool with respect to Indigenous Australian knowledges in radiation therapy. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation.

  10. Newman G, Brown A, Rumley C, Baines J, Hargrave C. Adaptive radiation therapy practices: an Australian perspective. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation

  11. Tabet C, Brown A, Brown S, Hargrave C. Hypofractionation utilisation in radiation therapy: a regional department evaluation. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation

  12. Brown A, Jones S, Yim J. Value-based health care – not just for the bean counters. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation

  13. Davidson A, Becker J, Nguyen M, Deegan L, Dang T, Otter T, Hargrave C. An evaluation of 6DoF corrections using extended field of view CBCT for CSI image guidance. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation

  14. Brown A, McCoola B, Funnel Y, Hargrave C. Meaningful consumer engagement in medical radiation sciences: enhancing quality improvement and research projects. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation

  15. Wan R, Brown E. Can open faced masks open the door for brain patients struggling with anxiety? ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Poster Presentation.

  16. Stephens E, King A, Barnes N, Mason N, Deegan T, Brown E, Hargrave C. A multi-centre survey of decision-making for image guided post-prostatectomy radiation therapy. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Poster Presentation

  17. Devonport B, McMahon K, Stewart K, Burbery J, Hargrave C. Evaluating the feasibility of total body photography in superficial radiation therapy. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation

  18. Hargrave C, Wallace N, Edeling D, Rose P, Scull A, Fisher C, Pallesen R, Rudd A, Knowles J, Bernard A, Zawlodzka S, Hewitt S, Lehman M. Outcomes and learning from a trial evaluating a topical silicone gel: Revisiting radiation dermatitis. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Oral presentation

  19. Blyth J, Hargrave C, Grogan M, Choma K. Evaluation of a customised radiation therapy bra for breast cancer patients with large pendulous breasts. ASMIRT 18th National Conference, Darwin, 9-12 May 2024. Poster Presentation.

  20. Puffett A. The Treatment Translation project. Clinical Excellence Showcase, Brisbane, 15 May 2024. Oral Presentation

  21. Pullar A. Non-Craniopharyngioma Paediatric Cases: Impact on Hypothalamic Pituitary Axis (HPA) from Radiation. ANZPA, Gold Coast, 26-28 July 2024. Oral Presentation

  22. Huo M. Radiotherapy in pituitary disease – what the endocrinologist needs to know. Endocrine Society of Australia Seminar, Darwin, April 2024. Oral presentation

  23. Huo M . Complications in the management of pituitary disease: radiation cases.  ANZPA, Gold Coast, 26-28 July 2024. Oral Presentation

  24. McDowell L. Envisioning the Future: Leading Edge Research in HPV-Associated Oropharyngeal Cancer - ASTRO Annual Meeting, Washington, September 2024. Scientific session discussant

  25. McDowell L, Gough K, Fua T, Coleman A, Drosdowsky A, Rischin D, Corry J. Final analysis of a prospective study evaluating sexual health, facial appearance, and appearance distress in patients with human  papillomavirus-associated oropharyngeal cancer patients treated with (chemo)radiation (LASH). ASTRO Annual Meeting, Washington, September 2024. Poster presentation.

  26. McDowell L, Gough K, Fua T, Coleman A, Drosdowsky A, Rischin D, Corry J. Treatment Outcome Priorities for Patients with HPV-associated Oropharyngeal Cancer (HPVOPC) Before and 12 Months after Primary (Chemo)radiation (CRT/RT): Results from a Prospective Longitudinal Observational Study. ASTRO Annual Meeting, Washington, September 2024. Poster presentation

  27. Lee YY, Sengupta C, Nguyen D, Ball H, Chu J, Booth J, Van Gysen K, Hardcastle N, Moodie T, Liu SF, Brown E, Mason D, Tacon B, Zwan B, Tang SC, O’Brien R, Gebski V, Wang TW, Keall P. - Tracking the Invisible: Primary Analysis of Real-Time Image Guidance in Liver SBRT from the TROG 17.03 Lark Trial. ASTRO Annual Meeting, Washington, September 2024. Poster presentation.

  28. McDowell L, Gough K, Fua T, Coleman A, Drosdowsky A, Rischin D, Corry J - Final analysis of a prospective study evaluating sexual health, facial appearance, and appearance distress in patients with human papillomavirus-associated oropharyngeal cancer patients treated with (chemo)radiation (LASH) - ANZHNCS Annual Scientific Meeting, Melbourne, August 2024. Oral presentation.

  29. McDowell L - Facing the Shadows: Insights from Prospective Data and Clinician Perspectives on Fear of Cancer Recurrence. ANZHNCS Annual Scientific Meeting, Melbourne, August 2024. Oral Presentation.

  30. Noble C, Hajnorouzi H, Ramachandran P. Evaluation of dose measurement accuracy and uncertainty through the combination of TLD and OSLD methods for in-vivo dosimetry. EPSM Conference, Melbourne,17–20 Nov 2024. Oral Presentation.

  31. Ramachandran P. Evolving Role of AI in Oncology. Cancer Updates, Online event, November 2024. Invited Speaker

  32. Ramachandran P, McInerney N, Ukath J, Mehta A. A feasibility study of using 6 DOF robotic arm for the automation of MLC QA. EPSM Conference, Melbourne, 17 – 20 Nov 2024. Oral Presentation

  33. Ramachandran P, Colbert Z, Arrington D, Huo M, Pinkham M, Foote M. Enhancing the Quality of Gamma Knife Cone-Beam Computed Tomography Images Through Pix2Pix Generative Adversarial Networks. EPSM Conference, Melbourne, 17 – 20 Nov 2024. Oral Presentation

  34. Ramachandran P. Optimizing CBCT image quality with advanced deep learning algorithms. NZPEM, Palmerston North NZ, 13 May 2024. Invited Speaker

  35. Jones D, Pinkham M - A nurse-led pilot intervention supporting carers of patients with high-grade glioma. GAINS - COSA, Gold Coast, November 2024. Poster Presentation.

  36. Mitina N, Peterson T, Hargrave C, Guidi R. An update of a retrospective evaluation of the dosimetric parameters; conformity index and gradient index for patients with spine metastases treated with stereotactic body radiation therapy. ISRS  16th International Stereotactic Radiosurgery Society Congress, New York, May 2024. Poster Presentation

  37. Bloxham P, Effeney B, Fogarty D, Gibbs A, Jones S, Mitina N, Sim L, Simpson-Page E. Multi-Disciplinary Approach Implementing New Radiation Oncology AI Driven Treatment Software. Clinical Excellence Showcase, Brisbane, 15 May 2024. Oral Presentation

  38. Jones S. Professional Impact Considerations of AI in RT. AI Clinical Applications, ASMIRT QLD Branch CEC, 13 July 2024, Online Event. Invited speaker

  39. Brown A, McCoola B, Funnell Y, Hargrave C. Meaningful Consumer Engagement in Medical Radiation Sciences: Enhancing Quality Improvement and Research Projects. Herston Health Precinct Symposium, RBWH Education Centre,  2-4 September 2024. Poster Presentation

  40. Hargrave C. Research: Getting Going, Keeping Going. ASMIRT NQ Conference, Townsville, Aug 2024. Oral presentation – Invited speaker

  41. Hughes D - Cannulation in RT practice. - ASMIRT NQ Conference, Townsville, Aug 2024. Oral presentation

  42. Sharma H - MRI simulation impact on RT practice. ASMIRT NQ Conference, Townsville, Aug 2024. Oral presentation

  43. Sim L, Deegan T, Welch A, Mitchell J, Nguyen K, Barbera S, Simpson-Page E, Ratnayke G.  Using quadruple aims of healthcare as a framework for radiation therapy innovation. International Forum on Quality and Safety in Healthcare, Brisbane, 6 – 8th November 2024. Poster Presentation

  44. Simpson-Page E. Stronger Together: A physicists experience in health literacy. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Oral Presentation

  45. Sim L, Simpson-Page E, Crowe S, Cheuk R. Shaping the Future of Rib Reconstruction - Radiotherapy dosimetry for patients with implanted StarPore 3D printed ribs for chest wall reconstruction. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Oral Presentation

  46. Sim L, Hirning M, Mehta A, Arrington D,  Motley R, Seshadri V, Ramachandran P, Perrett B, Noble C, Horgan E. Dose Calculation  on kV Cone Beam CT images- Can there be a single workflow solution for a multi-vendor site?. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Oral Presentation

  47. Sim L, Hirning M, Kairn T, Crowe S, Hill R. Using low-cost copper for HVL measurements and the implications on dose to water determinations in medium energy x-ray beams. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Oral Presentation

  48. Nag A, Hargrave C, Pullar A, McMahon K, Crowley S. Evaluation of Portable MRI Compared to 3T MRI to Contour Brain Anatomy for Radiotherapy Planning. ASMIRT QLD CEC Student Paper Night, Online event, 17 September 2024.  Oral Presentation

  49. Wright. G, Choma K., Hargrave C, Pollard N, Stewart K. Evaluation of ExacTrac Dynamic Pre-Positioning Accuracy and Efficiency versus Tattoo-Based Positioning for Chest Radiation Therapy. ASMIRT QLD CEC Student Paper Night, Online event, 17 September 2024, Oral Presentation Awarded Best RT Student Paper Prize

  50. Alfifi R, Esposito A, Sim L. Developing novel solid phantom for quality assurance of eye plaques - Can film measurement identify source defects?  Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Oral Presentation

  51. Byrnes K, Sim L. Effect on superficial radiation surface dose due to application of sunscreen and other common creams. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Oral Presentation

  52. Pham HS, Haupt LM, Sim L, Ravichandran A,  Bray LJ. How well do 2D radiobiology models translate to a 3D tumour microenvironment? A study of 3D in vitro breast cancer cells treated using Fast Forward hypofractionated radiotherapy. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, 17 - 20 November 2024, Grand Hyatt Melbourne, 2024. Oral Presentation

  53. Miller J, Sim L. Shaping Independent Monitor Unit Verification in Electron Treatment Plans- Evaluating the Accuracy of Curvature Correction Factors in Eclipse and Pinnacle Calculations. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Poster Presentation

  54. Jones H, Sim L, Chan M, Hirning M. Harmonising Engineering and Physics in Clinical practice- A Multidisciplinary Approach from Design, Manufacturing and Dosimetry in the Commissioning of a HVL Jig. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Poster Presentation

  55. Simpson-Page E, Miller J, Boyd J. Cheers for 10 years: A decade of CT QA results to inform future QA frequency and tolerances. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Poster Presentation

  56. Miller J, Simpson-Page E. Computed Tomography (CT) Dose Alert Review. Engineering and Physical Sciences in Medicine Conference and Australian Biomedical Engineering Conference, Grand Hyatt Melbourne, 17 - 20 November 2024. Poster Presentation

  57. Pham SH, Ratnayake G, Sim L, Adams MN,Fielding AL, Haupt LM, Ravichandran A, Bray LJ. Application of in vitro 3D models to study the effect of hypofractionated radiation therapy for breast cancer. San Antonio Breast Cancer Symposium, San Antonio, Texas 78229 USA, December 10, 2024. Poster Presentation

Publications

Published Abstracts

  1. Scott A, Francis R, Lee ST, Eddie L, Whitehead A, Cook O, Barry N, Ebert M, Gan H, Moffat B, Fitt G, Moore A, Thomas P, Pattison D, Akhurst T, Alipour R, Thomas E, Schembri G, Hsiao E, Lin P, Ly T, Pinkham MB, Yap J, Kirkwood I, Vallat W, Khan S, Krishna D, Ngai S, Yu C, Beuzeville S, Yeow TC, Wong D, McGuiness M, Bailey D, Dykyj R, Rossi A, Evans H, Koh E. Multi-site, prospective trial evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Central review of initial FET-PET biologic target volume delineation for radiation planning. MN Symposium: Precision Medicine – neuro-oncology. Oral abstract. Vienna, Austria 2024.

  2. Chiew KL, Chong S, Sundaresan P, Lehman M, Vinod SK (20204). Real world measurement of lung radiotherapy quality indicators- better data for better care delivery. Poster Presentation. Radiotherapy and Oncology.194(s1):1730-1733.

  3. Knesl A, Panizza J, Pinkham MB, Shanker MD, Foley H, Lusk R, Hall B, Inder W, Olson S, Watkins T, Foote MC, Huo M. Clinical outcomes following hypo fractionated stereotactic radiotherapy for sellar and para-sellar tumours contacting the optic chiasm. Oral Presentation. ANZPA, Gold Coast 2024.

  4. Huo M, Shanker MD, Lusk R, Jones C, Ramachandran P, Jenkins M, King S, Watkins T, Hall B, Olson S, Pinkham MB, Foote MC. Factors predicting for local failure following Gamma Knife radiosurgery to small melanoma brain metastases: impact of distance from isocenter, prescription isodose and beam-on time. Oral Presentation. ISRS Congress. New York, USA 2024.

  5. Shanker M, Foley H, Crowley S, Lusk R, Muscat K, Le Cornu E, Huo M, Foote MC, Pinkham MB, Volumetric tumour response in patients treated with combination stereotactic radiosurgery and immunotherapy for melanoma brain metastases. Oral Presentation. ISRS Congress. New York, USA 2024. - Prize winning presentation (ISRS Young Professional Award).

  6. Udovicich C, Koo K, Bryant J, Bugarini A, Huo M, Kim K, Li Y, Oliver D, Patel S, Rogers S, Chicoine M, Foote MC, Kim S, Mahadevan A, Pinkham MB, Sia J, Haghighi N. International collaboration of neoadjuvant stereotactic radiosurgery for brain metastases (INTERNEO): an individual patient data meta-analysis. Oral Presentation. ISRS Congress. New York, USA 2024.

  7. Johns E, Bernard A, Nissen L, Barry T, Pinkham M, Hargrave C. Validating predictive models for normal brain dose in stereotactic radiotherapy for single brain metastases. Oral Presentation J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  8. Cameron C, Brown E, Pollard N. Evaluation of image verification shifts in VMAT breast and nodal patients and potential influencing factors. Oral Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024. (Awarded Best RT Student Paper Prize).

  9. Hargrave C, Wallace N, Edeling D, Rose P, Scull A, Fisher C, Pallesen R, Rudd A, Knowles J, Bernard A, Zawlodzka S, Hewitt S, Lehman M. Outcomes and learnings from a trial evaluating a topical silicone gel: revisiting radiation dermatitis. Oral Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  10. McCullough B, Burbery J, Chamunyonga C, Naidoo T. Development of a cultural capability tool with respect to Indigenous Australian knowledges in radiation therapy. Oral Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  11. Newman G, Brown A, Rumley C, Baines J, Hargrave C. Adaptive radiation therapy practices: an Australian perspective. Oral Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  12. Tabet C, Brown A, Brown S, Hargrave C. Hypofractionation utilisation in radiation therapy: a regional department evaluation. Oral Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  13. Brown A, Jones S, Yim J. Value-based health care – not just for the bean counters. Oral Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  14. Devonport B, McMahon K, Stewart K, Burbery J, Hargrave C. Evaluating the feasibility of total body photography in superficial radiation therapy. Oral Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  15. Davidson A, Becker J, Nguyen M, Deegan L, Dang T, Otter T, Hargrave C. An evaluation of 6DoF corrections using extended field of view CBCT for CSI image guidance. Oral Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  16. Brown A, McCoola B, Funnel Y, Hargrave C. Meaningful consumer engagement in medical radiation sciences: enhancing quality improvement and research projects. Oral Presentation. . J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  17. Wan R, Brown E. Can open faced masks open the door for brain patients struggling with anxiety? Poster Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  18. Stephens E, King A, Barnes N, Mason N, Deegan T, Brown E, Hargrave C. A multi-centre survey of decision-making for image guided post-prostatectomy radiation therapy. Poster Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  19. Blyth J, Hargrave C, Grogan M, Choma K. Evaluation of a customised radiation therapy bra for breast cancer patients with large pendulous breasts. Poster Presentation. J Med Radiat Sci. 2024; 71(S1): 2051-3895 https://doi.org/10.1002/jmrs.765 Special Issue: ASMIRT 2024: Colours of Country – Community, Resilience, Innovation. Annual Scientific Meeting of Medical Imaging and Radiation Therapy – 18th National Conference. Darwin 2024.

  20. Jeon MS, He S, Shaw J, Koh E, Kelly B, Pinkham MB, Legge DM, Halkett G, Chan RJ, Ownsworth T, Sansom-Daly U, Kastelan M, Dhillon H. What constitutes optimal care coordination for primary brain tumours and how do we assess it in Australia: a Delphi consensus study. Oral abstract. COGNO ASM. Melbourne 2024.

  21. Jeon MS, Shaw J, Banks H, Legge DM, He S, Carlick T, Koh E, Halkett G, Kelly B, Pinkham MB, Ownsworth T, Chan RJ, Dhillon H. Coordination of care in the context of primary brain tumours: healthcare professionals’ exploration of the unspoken impact and clinical implications. Oral abstract. COGNO ASM. Melbourne 2024.

  22. Carlick T, Kirsten S, Campbell R, Faris MM, Jeon MS, Legge DM, Chan RJ, Pinkham MB, Koh ES, Halkett GKB, Kelly B, Haydon HM, Sansom-Daly U, Agar MR, Pike KE, Lion KM, Shaw JM, Dhillon HM. The effectiveness of non-pharmacological interventions to reduce cancer-related fatigue in people with primary brain tumours: a systematic review. Oral abstract. COGNO ASM. Melbourne 2024.

  23. Pike KE, Virtue-Griffiths SEB, Moller CI, Legge DM, Pinkham MB, Vuksanovic D, Saliba L, Shaw J,Dhillon HM. A randomised controlled trial of a telehealth group cognitive intervention (BRAINS-LaTCH) for people with primary brain tumour. Oral abstract. COGNO ASM. Melbourne 2024.

  24. Kazi A, Arrington D, Ramachandran P, Pinkham M, Reutens D. Radiomic models to predict survival and IDH mutation in glioma patients: impact of delineation accuracy. Poster. COGNO ASM. Melbourne 2024

  25. Chelvarajah R, Liefman D, Chako A, Watkins T, Ong B, Porter R, Volp A, Law P, Jagger G, Turner J, McGill G, Ngai S, Shanker M, Huo M, Foote M, Pinkham MB. Role of FET-PET in assessing enhancing changes after radiosurgery to differentiate between tumour progression and radionecrosis Poster. COGNO ASM. Melbourne 2024.

  26. Scott A, Francis R, Lee ST, Eddie L, Whitehead A, Cook O, Barry N, Ebert M, Gan H, Moffat B, Fitt G, Moore A, Thomas P, Pattison D, Akhurst T, Alipour R, Thomas E, Schembri G, Hsiao E, Lin P, Ly T, Pinkham MB, Yap J, Kirkwood I, Vallat W, Khan S, Krishna D, Ngai S, Yu C, Beuzeville S, Yeow TC, Wong D, McGuiness M, Bailey D, Dykyj R, Rossi A, Evans H, Koh E. Multi-site, prospective trial evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Preliminary results of central nuclear medicine review of FET-PET biologic target volume delineation for radiation planning.  Oral abstract. SNO. Houston, USA 2024.

  27. Jones D, Chan RJ, Pinkham MB, Thamm C, Strodl E, Beesley V, Wallen M P. Glioma carers-assessment of individual needs and support: Protocol for a single arm pilot study. CNSA ASM. Brisbane 2024.

  28. Mylonas A, Nguyen DT, Seshadri V, Ramachandran P, Keall P. Deep learning-based contrast agent segmentation for liver cancer targeting during radiation therapy. ESTRO, Glasgow UK, 2024.

  29. Alam FI, Field M, Al Mouiee D, Chlap P, Ramachandran P, Holloway L. Streamlining Radiotherapy Structure Nomenclature: A Multimodal Feature Learning Approach. ESTRO, Glasgow UK, 2024.

Research Articles

  1. McDowell L, Barnett C. The Crown Jewel: Checkpoint Inhibition in Unresectable Cutaneous Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):9. doi: 10.1016/j.ijrobp.2023.11.017. PMID: 38631751.

  2. Smith J, Margalit D, Golledge J, Nastasi D, Nohria A, McDowell L. Carotid Artery Stenosis and Ischemic Stroke in Patients with Head and Neck Cancer Treated with Radiotherapy: A Critical Review. Int J Radiat Oncol Biol Phys. 2024 Apr 5:S0360-3016(24)00474-7. doi: 10.1016/j.ijrobp.2024.03.044. Epub ahead of print. PMID: 38583496.

  3. Jabbour SK, Kumar R, Anderson B, Chino JP, Jethwa KR, McDowell L, Lo AC, Owen D, Pollom EL, Tree AC, Tsang DS, Yom SS. Combinatorial Approaches for Chemotherapies and Targeted Therapies With Radiation: United Efforts to Innovate in Patient Care. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1240-1261. doi: 10.1016/j.ijrobp.2024.01.010. Epub 2024 Jan 10. PMID: 38216094.

  4. Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, Chua ML, de Ridder M, Garikipati S, Hanai N, Ho FCH, Huang SH, Kiyota N, Klinghammer K, Kowalski LP, Kwong DL, McDowell LJ, Merlano MC, Nair S, Economopoulou P, Overgaard J, Psyrri A, Tribius S, Waldron J, Yom SS, Mehanna H. Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database. Eur J Cancer. 2024 Mar 30;203:114038. doi: 10.1016/j.ejca.2024.114038. Epub 2024 Mar 30. PMID: 38579517.

  5. McDowell L, Gough K, Fua T, Coleman A, Drosdowsky A, Rischin D, Corry J. A Longitudinal Study Evaluating Sexual Health Outcomes and Prioritization in Patients Undergoing Chemoradiation for Human Papillomavirus-Associated Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2024 Mar 15;118(4):1018-1028. doi: 10.1016/j.ijrobp.2023.10.006. Epub 2023 Oct 20. PMID: 37865126.

  6. Corry J, Moore A, Kenny L, Wratten C, Fua T, Lin C, Porceddu S, Liu C, Ruemelin M, Sharkey A, McDowell L, Wilkinson D, Tiong A, Rischin D. Radiotherapy quality assurance in the TROG 12.01 randomised trial and its impact on loco-regional failure. Front Oncol. 2024 Feb 5;13:1333098. doi: 10.3389/fonc.2023.1333098. PMID: 38375205; PMCID: PMC10875123.

  7. Phillips C, Pinkham MB, Moore A, Sia J, Jeffree RL, Khasraw M, Kam A, Bressel M, Haworth A. Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02). Breast. 2024 Apr;74:103675. doi: 10.1016/j.breast.2024.103675. Epub 2024 Feb 5. PMID: 38340685; PMCID: PMC10869940.

  8. Barry N, Koh ES, Ebert MA, Moore A, Francis RJ, Rowshanfarzad P, Hassan GM, Ng SP, Back M, Chua B, Pinkham MB, Pullar A, Phillips C, Sia J, Gorayski P, Le H, Gill S, Croker J, Bucknell N, Bettington C, Syed F, Jung K, Chang J, Bece A, Clark C, Wada M, Cook O, Whitehead A, Rossi A, Grose A, Scott AM. [18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program. Phys Imaging Radiat Oncol. 2024 Mar 13;30:100568. doi: 10.1016/j.phro.2024.100568. PMID: 38585372; PMCID: PMC10998205.

  9. Ratnayake G, Huo M, Mehta A, Ramachandran P, Pinkham MB, Law P, Watkins T, Olson S, Hall B, Brown S, Lusk R, Jones C, O'Mahoney E, McGill G, Foote MC. Utility of 68Ga-DOTATATE PET-MRI for Gamma Knife® stereotactic radiosurgery treatment planning for meningioma. Br J Radiol. 2024 Jan 23;97(1153):180-185. doi: 10.1093/bjr/tqad026. PMID: 38263827; PMCID: PMC11027229.

  10. Grahvendy, M., Brown, B. & Wishart, L.R. Adverse Event Reporting in Cancer Clinical Trials: Incorporating Patient-Reported Methods. A Systematic Scoping Review. Patient (2024). https://doi.org/10.1007/s40271-024-00689-4.

  11. Siva S, Moon D, Pryor D. Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply. Lancet Oncology volume 25(6); E230, June 2024.

  12. Gaudreault M, Hardcastle N, Jackson P, McIntosh L, Higgs B, Pryor D, Sidhom M, Dykyj R, Moore A, Kron T, Siva S. Dose-effect Relationship of Kidney Function After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: Trog 15.03 Fastrack Il. Int J Radiat Oncol Biol Phys. 2024 Apr 26:S0360-3016(24)00564-9. doi: 10.1016/j.ijrobp.2024.04.066. Epub ahead of print. PMID: 38679212.

  13. Deek MP, Sutera P, Jing Y, Gao R, Rothman E, Day H, Chang D, Dirix P, Armstrong AJ, Campbell B, Lopez Campos F, Berenguer M, Ramotar M, Conde-Moreno A, Berlin A, Bosetti DG, Corcoran N, Koontz B, Mercier C, Siva S, Pryor D, Ost P, Huynh MA, Kroeze S, Stish B, Kiess A, Trock B, Tran PT, Gillessen S, Sweeney C. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol. 2024 Apr 2:S2588-9311(24)00086-5. doi: 10.1016/j.euo.2024.03.010. Online ahead of print. PMID: 38570239.

  14. Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, Lourenco RDA, Shaw M, Mancuso P, Moon D, Wong L, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2. PMID: 38423047 Clinical Trial.

  15. Maher AM, Shanker M, Liu HYH, Lee Y, Leggett D, Hodgkinson P, Pryor D, Stuart KA. Comparison of outcomes following surgical resection, percutaneous ablation or stereotactic body radiation therapy in early-stage, solitary and small (≤3 cm) treatment-naïve hepatocellular carcinoma. Cancer Med. 2024 Feb;13(3):e6978. doi: 10.1002/cam4.6978.  PMID: 38400681 Free PMC article. 

     

  16. Wegener E, Sidhom M, Pryor D, Bucci J, Yeoh K, Richardson M, Greer P, Wilton L, Gallagher S, Schmidt L, Arumugam S, Keats S, Brown S, Glyde A, Martin JM.  Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial. Eur Urol Oncol. 2024 Jan 31:S2588-9311(24)00033-6. doi: 10.1016/j.euo.2024.01.008. Online ahead of print. PMID: 38302321.

  17. Magon H, Smith J, Besson J, Hau Eric, Taylor S, Ruben J, Jones D, Mabb K, Feldman J, Gholam Rezaei L, Lee YY. Adapting to change: exploring perceptions and demands of the coronavirus (COVID-19) workforce changes – an Australian multi-institutional radiation oncology survey. Australian Health Review. 2024. doi: https://doi.org/10.1071/AH23183.

  18. Smith J, Porceddu SV. Regional Radiotherapy in Head and Neck Non-melanoma Skin Cancer. In: Radiotherapy in Skin Cancer. 2024. doi: https://doi.org/10.1007/978-3-031-44316-9_14.

  19. Donnelly C, Or M, Toh J, Thevaraja M, Janssen A, Shaw T, Pathma-Nathan N, Harnett P, Chiew KL, Vinod S, Sundaresan P. Measurement that matters: A systematic review and modified Delphi of multidisciplinary colorectal cancer quality indicators. Asia Pac J Clin Oncol. 2024 Apr;20(2):259-274. doi: 10.1111/ajco.13917. Epub 2023 Feb 1. PMID: 36726222.

  20. Lord SJ, Daniels B, O'Connell DL, Kiely BE, Beith J, Smith AL, Pearson SA, Chiew KL, Bulsara MK, Houssami N. Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001-2016. Cancer Epidemiol Biomarkers Prev. 2024 Feb 6;33(2):314-324. doi: 10.1158/1055-9965.EPI-23-0942. PMID: 38015752.

  21. McDowell L, Gough K, White I, Corry J, Rischin D. Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer - A narrative review. Oral Oncol. 2024 Jul 30;157:106975. doi: 10.1016/j.oraloncology.2024.106975. Epub ahead of print. PMID: 39083855.

  22. Lim AM, McDowell L, Hurt C, Le Tourneau C, Homma A, Shenouda G, Thomson DJ, Moya-Plana A, Henson C, Szturz P, Day AT, Bates JE, Lazarakis S, Thariat J, Psyrri A, Mehanna H, Yom SS; HNCIG. Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul;25(7):e318-e330. doi: 10.1016/S1470-2045(24)00067-6. PMID: 38936390.

  23. Lim AM, Le Tourneau C, Hurt C, Laskar SG, Steuer CE, Chow VLY, Szturz P, Henson C, Day AT, Bates JE, Lazarakis S, McDowell L, Mehanna H, Yom SS; HNCIG. Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul;25(7):e308-e317. doi: 10.1016/S1470-2045(24)00068-8. PMID: 38936389.

  24. Henson C, Abou-Foul AK, Yu E, Glastonbury C, Huang SH, King AD, Lydiatt WM, McDowell L, Nagelschneider AA, Nankivell PC, O'Sullivan B, Rhys R, Xiao Y, Andrew D, Asmussen JT, Bidault F, Dankbaar JW, de Graaf P, Gebrim ES, Hu C, Ding J, Kanda T, Kim J, Kuno H, Medrano-Martorell S, Oikonomopoulos N, Goh JP, Santos-Armentia E, Schafigh DG, Subramaniam RM, Wu XC, Yom SS, Mehanna H. Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul;25(7): e297-e307. doi: 10.1016/S1470-2045(24)00066-4. PMID: 38936388.

  25. Abou-Foul AK, Henson C, Chernock RD, Huang SH, Lydiatt WM, McDowell L, O'Sullivan B, Perez-Ordonez B, Robinson M, Nankivell PC, Ruiz-Bravo E, Chiosea SI, Green TM, Hunter KD, Hwang JS, Koljenovic S, Koppes SA, Larsen SR, Lo AWI, Costes-Martineau V, Mittal N, Mori T, Nagao T, Panayiotides IG, Pinto CAL, Scheckenbach K, Seethala RR, Ulhøi BP, Vingiani A, Zhang Y, Yom SS, Mehanna H. Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul;25(7):e286-e296. doi: 10.1016/S1470-2045(24)00143-8. PMID: 38936387.

  26. Wilke C, Henson C, Huang SH, Bakst RL, Ng WT, Paterson C, McDowell L. Optimizing Therapy: The Art and Science of Modern Head and Neck Radiation. Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):709-715. doi: 10.1016/j.ijrobp.2023.12.014. PMID: 38851266.

  27. McDowell L, King MT, Hutcheson KA, Ringash J, Yom SS, Corry J, Henson C, Mehanna H, Rischin D. A Hard Truth to Swallow: Critically Evaluating the MD Anderson Dysphagia Inventory (MDADI) as an Endpoint in Human Papillomavirus- associated Oropharyngeal Cancer Trials. Int J Radiat Oncol Biol Phys. 2024 May 11:S0360-3016(24)00628-X. doi: 10.1016/j.ijrobp.2024.05.005. Epub ahead of print. PMID: 38740309.

  28. Hering H, Effeney B, Brady C, Hargrave C. An evaluation of ankle and foot bolus in paediatric modulated arc total body irradiation (MATBI). J Med Radiat Sci. 2024 Sep;71(3):355-364. doi: 10.1002/jmrs.780. Epub 2024 Mar 12. PMID: 38468597; PMCID: PMC11569397.

  29. Cooke S, Golusin N, Rattray G, Blyth J, Parkinson M, Hargrave C. The development and implementation of a radiation therapy bariatric protocol. J Med Radiat Sci. 2024 Sep;71(3):484-490. doi: 10.1002/jmrs.813. Epub 2024 Jul 14. PMID: 39003637; PMCID: PMC11569418.

  30. Simpson-Page E, Basaula D, Crowe SB. Quality management. 2023. In: 3D Printing in Radiation Therapy [Internet]. IOP Publishing; [7.1-18]. Available from: https://dx.doi.org/10.1088/978-0-7503-3907-0ch7.

  31. Basaula D, Simpson-Page E, Crowe SB, Kairn T. Treatment verification. 2023. In: 3D Printing in Radiation Therapy [Internet]. IOP Publishing; [10.1-21]. Available from: https://dx.doi.org/10.1088/978-0-7503-3907-0ch10.

  32. Effeney B, Pullar A, Burbery J, Hargrave C, Brady C. Dose to organs at risk for total body irradiation: Single-institution data using the modulated arc total body irradiation technique. Pediatr Blood Cancer. 2024 Sep;71(9):e31164. doi: 10.1002/pbc.31164. Epub 2024 Jul 2. PMID: 38953144.

  33. Brown E, Barry T, Mai T, Harvey J. Clinical experience of a tattoo application device. Technical Innovations and Patient Support in Radiation Oncology. 2024 June. Vol 30. https://doi.org/10.1016/j.tipsro.2024.100254.

  34. Jones N, Scott M, Mitchell J, Wallace N, Brown E, Hargrave C. The empathy project: Staff confidence and training needs in psychosocial patient care. J Med Imaging Radiat Sci. 2024 Dec;55(4):101735. doi: 10.1016/j.jmir.2024.101735. Epub 2024 Aug 27. PMID: 39197290.

  35. Mitchell J, Campbell A, Zhao M, Harvey J, Mai GT, Lee YY. Optimising PTV margins in oesophageal cancer radiotherapy: A modern radiotherapy planning, treatment delivery and verification approach - A single institutional analysis. J Med Imaging Radiat Oncol. 2024 Oct;68(7):853-861. doi: 10.1111/1754-9485.13738. Epub 2024 Oct 18. PMID: 39423343.

  36. Ebrahimi A, Gupta R, McDowell L, Magarey MJR, Smith PN, Schulte KM, Perriman DM, Veness M, Porceddu S, Low TH, Fowler A, Clark JR. Determinants of Prognosis in Head and Neck Cutaneous Squamous Cell Carcinoma With Nodal Metastases. JAMA Otolaryngol Head Neck Surg. 2024 Sep 26:e243103. doi: 10.1001/jamaoto.2024.3103. Epub ahead of print. PMID: 39325436; PMCID: PMC11428024.

  37. Green L, McDowell L, Ip F, Tapia M, Zhou M, Fahey MT, Dixon B, Magarey M. Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma. Oral Oncol. 2024 Sep 17;159:107032. doi: 10.1016/j.oraloncology.2024.107032. Epub ahead of print. PMID: 39293101.

  38. Ebrahimi A, Gupta R, McDowell L, Magarey MJR, Smith PN, Schulte KM, Perriman DM, Veness M, Porceddu S, Low TH, Fowler A, Clark JR. Predictors of distant metastatic recurrence in head and neck cutaneous squamous cell carcinoma with lymph node metastases treated with curative intent: A multicenter study. Head Neck. 2024 Aug 9. doi: 10.1002/hed.27912. Epub ahead of print. PMID: 39119874.

  39. Nicol C, Pinkham M, Foote M, McBean A, Conlon E, Ownsworth T. Patient Reported Outcomes and Short-Term Adjustment Trajectories Following Gamma Knife Radiosurgery for Benign Brain Tumor. Disability and Rehabilitation. 2024 Sept 12:1-10. doi: 10.1080/09638288.2024.2401631. Epub ahead of print. PMID: 39263895.

  40. Robledo KP, Lefresne S, Soon YY, Sahgal A, Pinkham MB, Nichol A, Soo RA, Parmar A, Hegi-Johnson F, Doherty M, Solomon BJ, Shultz DB, Tham IW, Sacher AG, Tey J, Leong CN, Koh WY, Huang Y, Ang YLE, Low J, Yong C, Lim MC, Tan AP, Lee CK, Ho C. Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration. BMJ Open. 2024 Jul 5; 14(7): e078335. doi: 10.1136/bmjopen-2023-078335. PMID: 38969367; PMCID: PMC11227758.

  41. Lion KM, Jamieson A, Billin A, Jones S, Pinkham MB, Ownsworth T. “It was never about me”: A qualitative inquiry into the experiences of psychological support and perceived support needs of family caregivers of people with high-grade glioma. Palliative Medicine. 2024 Sept;38(8):874-883. doi: 10.1177/02692163241261211. Epub 2024 Jun 25. PMID: 38916277.

  42. Pinkham MB, Herschtal A, Hong AM, Chua MS, Scolyer RA, Cumming S, Pullar A, Nobes J, Barker CA, Guadagnolo BA, Fogarty GB, Burmeister BH, Foote MC. The role of post-operative radiation therapy following wide excision of neurotropic melanoma of the head and neck; now and into the future. Annals Surgical Oncology. 2024 Sept; 31(9):6118-6119. doi: 10.1245/s10434-024-15657-3. Epub 2024 Jun 24. PMID: 38914835; PMCID: PMC11300567.

  43. Pinkham MB, Herschtal A, Hong AM, Chua MS, Scolyer RA, Cumming S, Pullar A, Nobes J, Barker CA, Guadagnolo BA, Fogarty GB, Burmeister BH, Foote MC. Randomised trial of post-operative radiation therapy following wide excision of neurotropic melanoma of the head and neck (RTN2 trial 01.09). Annals Surgical Oncology. 2024 Sept; 31(9):6088-6096. doi: 10.1245/s10434-024-15569-2. Epub 2024 Jun 8. PMID: 38851639; PMCID: PMC11300506.

  44. Morton Colbert Z, Arrington D, Foote M, Gårding J, Fay D, Huo M, Pinkham M, Ramachandran P. Repurposing traditional U-Net predictions for sparse SAM prompting in medical image segmentation. Biomed Phys Eng Express. 2024 Jan 4;10(2). doi: 10.1088/2057-1976/ad17a7. PMID: 38118182.

  45. Martin JA, Hart NH, Bradford N, Naumann F, Pinkham MB, Pinkham EP, Holland JJ. Exercise as a non-pharmacological intervention for the management of sleep disturbance in primary brain tumour survivors and their caregivers: a study protocol of a clinical trial. J Sports Medicine Australia Plus. 2024;3. doi: 10.1016/j.jsampl.2024.100059.

  46. Faris MM, Dhillon HM, Campbell R, Halkett GKB, Miller A, Chan RJ, Haydon HM, Sansom-Daly UM, Koh ES, Ownsworth T, Nowak AK, Kelly B, Leonard R, Pike KE, Legge DM, Pinkham MB, Agar MR, Shaw J, BRAINS Program Group.  Unmet needs in people with high-grade glioma: Defining criteria for stepped care intervention. JNCI Cancer Spectrum. 2024 Jul;8(4): pkae034. doi: 10.1093/jncics/pkae034. PMID: 38730547; PMCID: PMC11218915.

  47. Young RJ, Angel C, Bressel M, Pizzolla A, Thai AA, Porceddu SV, Liu H, Idrizi R, Metta J, Lim AM, Solomon BJ. Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer. Oral Oncology. 2024 Mar;150:106687. doi: 10.1016/j.oraloncology.2024.106687. Epub 2024 Jan 22. PMID: 38262249.

  48. Ladwa R, Chandra J, Woo W-P, Finlayson N, Liu H, McGrath M, See A, Hughes BG, Cooper CL, Jackson JE, Dzienis M, Xu Y, Panizza B, Frazer I and Porceddu SV. A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma. Front Oncol. 2024 Jul 5;14:1419258. doi: 10.3389/fonc.2024.1419258. PMID: 39035738; PMCID: PMC11258395.

  49. Barnett C, Bowman J, Ladwa R, McGrath M, Liu H, Gandhi M, Zahir SF, Porceddu S, Panizza B. Long-term outcomes in advanced anterior skull base malignancy: a single quaternary institution experience. ANZ J Surg. 2024 Dec;94(12):2165-2172. doi: 10.1111/ans.19144. Epub 2024 Jul 1. PMID: 38946707.

  50. Gyorki DE, Bae S, Smith RC, Caruso DA, Coker D, Connolly EA, Desai J, Johnston A, Lawless AK, Lazarakis S, Lo H, Maclean F, Mar J, McDonough J, Perianayagam G, Phillips M, Pryor D, Sundaram A, Thompson SR, Zhou DD, Hong AM. Update of clinical practice guidelines for the management of patients with sarcoma. ANZ J Surg. 2024 Oct 30. doi: 10.1111/ans.19293. Online ahead of print.PMID: 39475177 No abstract available.

  51. Ali M, Kwon YS, Koo K, Bruynzeel A, Pryor D, Schep DG, Huo M, Stein M, Swaminath A, Hannan R, Siva S. Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer. BJU Int. 2025 Jan;135(1):110-116. doi: 10.1111/bju.16520. Epub 2024 Aug 26.PMID: 39187428.

  52. Arumugam S, Young T, Jones C, Pryor D, Sidhom M. Treatment accuracy of standard linear accelerator-based prostate SBRT: the delivered dose assessment of patients treated within two major clinical trials using an in-house position monitoring system. Front Oncol. 2024 Aug 9;14:1372968. doi: 10.3389/fonc.2024.1372968. eCollection 2024.PMID: 39184052 Free PMC article.

  53. Wigg A, Tibballs J, Woodman R, Stuart K, Le H, Roberts SK, Olynyk JK, Strasser SI, Wallace M, Martin J, Haworth A, Hardcastle N, Loo KF, Tang C, Lee YY, Chu J, De Abreu Lourenco R, Koukourou A, De Boo D, McLean K, Buck J, Sawhney R, Nicoll A, Dev A, Wood M, Braund A, Weltman M, Khor R, Levy M, Wang T, Potter M, Haridy J, Raj A, Duncan O, Zekry A, Collier N, O'Beirne J, Holliday C, Trada Y, Tronidjaja J, George J, Pryor D. A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC). BMC Cancer. 2024 Jul 8;24(1):813. doi: 10.1186/s12885-024-12504-2.PMID: 38973009 Free PMC article. Clinical Trial.

  54. Pattenden TA, Thangasamy IA, Ong WL, Samaranayke D, Morton A, Murphy DG, Evans S, Millar J, Chalasani V, Rashid P, Winter M, Vela I, Pryor D, Mark S, Loeb S, Lawrentschuk N, Pritchard E. Barriers and enablers of active surveillance for prostate cancer: a qualitive study of clinicians. BJU Int. 2024 Feb;133 Suppl 3:48-56. doi: 10.1111/bju.16176. Epub 2023 Sep 27.PMID: 37696615.

  55. Mowery YM, Ballman KV, Hong AM, Schuetze SM, Wagner AJ, Monga V, Heise RS, Attia S, Choy E, Burgess MA, Bae S, Pryor D, Van Tine BA, Tinoco G, Chmielowski B, Freeman C, Gronchi A, Meyer CF, Dickson M A, Hartner L, Davis LE, Powers BC, Moding EJ, Weinhold KJ, van de Rijn M, Brigman BE, Riedel RF, Kirsch DG.  Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. Lancet. 2024 Nov 23;404(10467):2053-2064. doi: 10.1016/S0140-6736(24)01812-9. Epub 2024 Nov 12. PMID: 39547252.

  56. Knesl A, Mapp S, Tallis C, Lee YY. Tumour-directed radiotherapy as a successful bridge to curative chemotherapy in early stage Hodgkin’s lymphoma-associated vanishing bile duct syndrome. BMJ Case Reports. 2024;17(9):e261879. doi: 10.1136/bcr-2024-261879. PMID: 39317481.

  57. Plant N, Mylonas A, Sengupta C, Nguyen DT, Silvester S, Pryor D, Greer P, Lee YYD, Ramachandran P, Seshadri V, Trada Y, Khor R, Wang T, Hardcastle N, Keall P. Radio-opaque contrast agents for liver cancer targeting with KIM during radiation therapy (ROCK-RT): an observational feasibility study. Radiat Oncol. 2024;19(1):139. doi: 10.1186/s13014-024-02524-4.

  58. Webb PM, Brown A, Brown B, Collins LG, Crawford Williams F, Doupain K, Eastgate M, Fennelly V, Girgis A, Hartel G, Ladwa R, Martin K, Mason R, McGuire P, Miller E, O'Brien S, Packer R, Pinkham MB, Sabesan S, Sanmugarajah J, Slapp G, Tapsall D, White J, Wishart LR, Wyld D, Chan RJ. Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)-protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. BMJ Open. 2024 Nov 19;14(11):e090836. doi: 10.1136/bmjopen-2024-090836. PMID: 39566946; PMCID: PMC11580250.

  59. Mehta A, Horgan E, Ramachandran P, Noble C. A Cost-effective Breath-hold Coaching Camera System for Patients Undergoing External Beam Radiotherapy. Journal of Medical Physics. 2024 Oct 1;49(4):502-9. doi:10.4103/jmp.jmp_101_24.

  60. Min H, Hormaechea GS, Ramachandran P, Dowling J. Evaluating the Impact of Sequence Combinations on Breast Tumor Segmentation in Multiparametric MRI. arXiv preprint arXiv:2406.07813. 2024 Jun 12.

  61. Perrett B, Seshadri V, Huxley C, Kumar S, Wawrzak M, Ramachandran P. Evaluation of radiation detectors for the determination of field output factors in Leksell Gamma Knife dosimetry using 3D printed phantom inserts. Physica Medica. 2024 May 1;121:103370. doi: 10.1016/j.ejmp.2024.103370.

  62. Arrington D, Motley R, Colbert ZM, Lehman M, Ramachandran P. PAHPhysRAD: A Digital Imaging and Communications in Medicine Research Tool for Segmentation and Radiomic Feature Extraction. Journal of Medical Physics. 2024 Jan 1;49(1):12-21. doi: 10.4103/jmp.jmp_120_23.

  63. Sengupta C, Liu SF, Brown E, Wang T, Lee YY, Sullivan E, Ramachandran P, Poulsen P, Keall P. The first clinical implementation of real-time 6 degree-of-freedom image-guided radiotherapy for liver SABR patients. Radiotherapy and Oncology. 2024 Jan 1;190:110031. doi:10.1016/j.radonc.2023.110031.

  64. Naidoo T, Chamunyonga C, Burbery J, Rutledge P. Cultural safety in radiation therapy education: Identifying knowledge deficits to improve Indigenous health practice. J Med Radiat Sci. 2024 Dec;71(4):608-613. doi: 10.1002/jmrs.819. Epub 2024 Sep 8. PMID: 39245952; PMCID: PMC11638365.

  65. Warrender-Sparkes M, Tomaszewski JM, Ip C, Chander S, Christie D, Corcoran NM, Emmett L, Finnigan R, Hayden A, Higgs B, Horsley P, Holt T, Sasso G, Shakespeare TP, Sidhom M, Tree A, Kneebone A. Post-prostatectomy radiation therapy: Updated guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group (FROGG). Radiotherapy and oncology. 2025;204:110690. doi: 10.1016/j.radonc.2024.110690.

  66. Ades A, Holt T, Rhee H, Webb M, Mehdi AM, Ratnayake G. Prognostic value of PSMA PET in predicting long-term biochemical control following curative intent treatment for prostate cancer. J Med Imaging Radiat Oncol. 2025 Feb;69(1):129-135. doi: 10.1111/1754-9485.13787. Epub 2024 Oct 11. PMID: 39394722.

  67. Liu H, Hardcastle N, Bailey M, Siva S, Seeley A, Barry T, Booth J, Lao L, Roach M, Buxton S, Thwaites D, Foote M. Guidelines for safe practice of stereotactic body (ablative) radiation therapy: RANZCR 2023 update. J Med Imaging Radiat Oncol,2024, 68: 217-227. https://doi.org/10.1111/1754-9485.13618.

Collaborative Trials Portfolio

Trial Activity Table 2024

Acknowledgements in preparing the 2024 report 
 Rochelle Palleson, Sharon Watson, Anna Koch, Nakia Beaton, Dr Elizabeth Brown, Dr Cathy Hargrave, Andrew Puffett and all researchers listed in our 2024 PAH Radiation Oncology research report - Thank you!